<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00892697</url>
  </required_header>
  <id_info>
    <org_study_id>0810010040</org_study_id>
    <nct_id>NCT00892697</nct_id>
  </id_info>
  <brief_title>Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)</brief_title>
  <official_title>#0810010040: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus Infection: A Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys速) and Ribavirin (Copegus速) in Subjects With Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the decline of virus in the blood and liver in&#xD;
      patients treated with telaprevir, pegylated interferon and ribavirin.&#xD;
&#xD;
      Fine Needle Aspiration (FNA) procedure will be used to repeatedly sample the liver to enhance&#xD;
      the understanding of how the virus decays in the liver in response to treatment with&#xD;
      anti-viral compounds and the measurement of the concentration of the drugs in the liver. FNA&#xD;
      is an alternative procedure to core needle biopsy in its ability to repeatedly sample the&#xD;
      liver with significantly reduced morbidity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrahepatic and Plasma HCV Viral Kinetics</measure>
    <time_frame>Day-7, Day 1, Day 4,</time_frame>
    <description>Intrahepatic viral kinetics, plasma viral kinetics,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir</measure>
    <time_frame>Day 1, Day 4, Day 15, Week 8</time_frame>
    <description>Intrahepatic and plasma telaprevir concentration ratios</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if &gt;75 kg or 1000mg per day if &lt; 75 kg).</description>
    <arm_group_label>Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if &gt;75 kg or 1000mg per day if &lt; 75 kg).</description>
    <arm_group_label>Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if &gt;75 kg or 1000mg per day if &lt; 75 kg).</description>
    <arm_group_label>Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects, 18-65 years of age, inclusive.&#xD;
&#xD;
          2. Cases will be genotype 1 (confirmed by standard testing). Enrollment of controls will&#xD;
             not be restricted by genotype.&#xD;
&#xD;
          3. All patients must show evidence of chronic hepatitis C, confirmed by detectable plasma&#xD;
             HCV RNA. Chronic disease status must be confirmed by at least one of the following&#xD;
             standard criteria:&#xD;
&#xD;
             History of a remote risk factor, or Abnormal ALT levels for &gt;6 months prior to&#xD;
             screening period (Note: elevated ALT is not an inclusion criteria, if one of the other&#xD;
             criteria for &quot;chronic&quot; hepatitis C is met), or Detectable HCV RNA for at least 6&#xD;
             months before the screening period&#xD;
&#xD;
          4. Liver biopsy obtained within 24 months of study enrollment demonstrating absence of&#xD;
             cirrhosis (stage 0-3) for cases. Enrollment of controls will not be restricted by&#xD;
             stage of fibrosis.&#xD;
&#xD;
          5. Judged to be in good health on the basis of medical history and physical examination&#xD;
             (including vital signs and ECG), with any chronic medical conditions under stable&#xD;
             medical control.&#xD;
&#xD;
          6. Screening Visit laboratory values must be within the following:&#xD;
&#xD;
               -  Laboratory variable: acceptable range&#xD;
&#xD;
               -  Absolute neutrophil count: 1200/cmm続&#xD;
&#xD;
               -  Platelet count: 90,000/cmm続&#xD;
&#xD;
               -  Hemoglobin: within normal range&#xD;
&#xD;
               -  HbsAg (screening visit only): seronegative&#xD;
&#xD;
               -  HIV1 and 2 Ab (screening visit only): seronegative&#xD;
&#xD;
             In addition, all other hematology and clinical chemistry must be within normal limits&#xD;
             or show no clinically significant abnormalities.&#xD;
&#xD;
          7. Subjects (or their female partners) must be not pregnant, planning to become pregnant&#xD;
             within the next 72 weeks, or they must be permanently sterile or otherwise of non&#xD;
             childbearing potential. They must also not be breastfeeding. If of child-bearing&#xD;
             potential, subjects must agree to use 2 effective methods of contraception from&#xD;
             screening through 6 months after the last dose of RBV. Male subjects who have a female&#xD;
             partner of childbearing potential must agree to use 2 effective methods of&#xD;
             contraception from Screening through 7 months after the last dose of RBV unless&#xD;
             vasectomized.&#xD;
&#xD;
          8. Female subjects must have a negative pregnancy test at all visits (screening and&#xD;
             predose Day 1) before the first dose of study drugs.&#xD;
&#xD;
          9. Willing to refrain from the concomitant use of any medications, substances or foods.&#xD;
&#xD;
         10. Able to read and understand the Informed Consent Form (ICF) and willing to sign the&#xD;
             ICF and abide by the study requirements and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received more than 4 weeks of any approved or investigational drug or drug regimen for&#xD;
             the treatment of hepatitis C.&#xD;
&#xD;
          2. Any medical contraindications to Peg-IFN alpa-2a or RBV therapy, including any of the&#xD;
             following:&#xD;
&#xD;
               1. Abnormal thyroid stimulating hormone (TSH) levels or poorly controlled thyroid&#xD;
                  function&#xD;
&#xD;
               2. Evidence of clinically significant cardiac dysfunction;&#xD;
&#xD;
               3. History of psychiatric disorders determined by the investigator to contraindicate&#xD;
                  the use of IFN-based therapy;&#xD;
&#xD;
               4. Antinuclear antibody (ANA) titer 1:320;&#xD;
&#xD;
               5. History of hemoglobinopathies.&#xD;
&#xD;
          3. Patients coinfected with either human immunodeficiency virus (HIV) or hepatitis B&#xD;
             virus (HBV).&#xD;
&#xD;
          4. Decompensated liver disease as indicated by a history of ascites, hepatic&#xD;
             encephalopathy, or bleeding esophageal varices.&#xD;
&#xD;
          5. Diagnosed or suspected hepatocellular carcinoma. Alfa-fetoprotein (AFP) during&#xD;
             screening must be less than 100 ng/mL.&#xD;
&#xD;
          6. For cases, histologic evidence of hepatic cirrhosis on any liver biopsy&#xD;
&#xD;
             o Most recent liver biopsy must be within 2 years prior to study screening.&#xD;
&#xD;
          7. Has taken any of the prohibited medications within 28 days of initiation of therapy.&#xD;
&#xD;
          8. A history of any illness that, in the opinion of the investigator, might confound the&#xD;
             results of the study or pose an additional risk in administering study drug to the&#xD;
             subject. This may include but is not limited to a history of relevant drug or food&#xD;
             allergies, history of cardiovascular or central nervous system disease, history or&#xD;
             presence of clinically significant illness, or history of mental illness that may&#xD;
             affect compliance with study requirements.&#xD;
&#xD;
          9. Alcohol abuse or excessive use (in the opinion of the investigator, as judged by&#xD;
             medical history) in the last 12 months.&#xD;
&#xD;
         10. Participation in any investigational drug study within 90 days before drug&#xD;
             administration or participation in more than 2 drug studies in the last 12 months&#xD;
             (exclusive of the current study).&#xD;
&#xD;
         11. For cases, hypersensitivity to tartrazine (known as yellow dye #5).&#xD;
&#xD;
         12. Men whose female partners are pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew H. Talal, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Talal AH, Dimova RB, Zhang EZ, Jiang M, Penney MS, Sullivan JC, Botfield MC, Chakilam A, Sawant R, Cervini CM, Zeremski M, Jacobson IM, Kwong AD. Telaprevir-based treatment effects on hepatitis C virus in liver and blood. Hepatology. 2014 Dec;60(6):1826-37. doi: 10.1002/hep.27202. Epub 2014 Jul 31.</citation>
    <PMID>24811404</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>April 30, 2009</study_first_submitted>
  <study_first_submitted_qc>May 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2009</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>March 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 20, 2015</results_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatitis C</keyword>
  <keyword>FNA</keyword>
  <keyword>intrahepatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telaprevir/Peg-IFN/RBV</title>
          <description>15 subjects received Telaprevir in combination with pegylated interferon and ribavirin.&#xD;
Telaprevir: Fifteen subjects received the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if &gt;75 kg or 1000mg per day if &lt; 75 kg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telaprevir/Peg-IFN/RBV</title>
          <description>15 subjects received Telaprevir in combination with pegylated interferon and ribavirin.&#xD;
Telaprevir: Fifteen subjects received the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if &gt;75 kg or 1000mg per day if &lt; 75 kg).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="46.5" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intrahepatic and Plasma HCV Viral Kinetics</title>
        <description>Intrahepatic viral kinetics, plasma viral kinetics,</description>
        <time_frame>Day-7, Day 1, Day 4,</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir/Peg-IFN/RBV</title>
            <description>15 subjects will receive Telaprevir in combination with pegylated interferon and ribavirin and 5 additional subjects on standard of care.&#xD;
Telaprevir: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if &gt;75 kg or 1000mg per day if &lt; 75 kg). Additional 5 subjects be on standard of therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Intrahepatic and Plasma HCV Viral Kinetics</title>
          <description>Intrahepatic viral kinetics, plasma viral kinetics,</description>
          <units>log transformed copies/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma HCV RNA predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma HCV RNA 10 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma HCV RNA day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver HCV RNA predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver HCV RNA 10 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver HCV RNA day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir</title>
        <description>Intrahepatic and plasma telaprevir concentration ratios</description>
        <time_frame>Day 1, Day 4, Day 15, Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telaprevir/PEG-IFN/RBV</title>
            <description>15 subjects will receive Telaprevir in combination with pegylated interferon alfa-2a and ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir</title>
          <description>Intrahepatic and plasma telaprevir concentration ratios</description>
          <units>telaprevir liver to plasma conc ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>telaprevir liver/plasma conc ratio day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" lower_limit="0.4" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>telaprevir liver/plasma conc ratio day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" lower_limit="0.33" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>telaprevir liver/plasma conc ratio day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.34" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>telaprevir liver/plasma conc ratio week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" lower_limit="0.42" upper_limit="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were followed for up to 24 weeks post treatment cessation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telaprevir/PEG-IFN/RBV</title>
          <description>15 subjects will receive Telaprevir in combination with pegylated interferon and ribavirin and 5 additional subjects on standard of care.&#xD;
Telaprevir: Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if &gt;75 kg or 1000mg per day if &lt; 75 kg). Additional 5 subjects be on standard of therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Talal, MD</name_or_title>
      <organization>University at Buffalo</organization>
      <phone>716-888-4737</phone>
      <email>ahtalal@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

